In a recent study published in Cell Metabolism, Wenes et al.1 identified that the inhibition of mitochondrial pyruvate carrier (MPC) led to CD8+ memory T cell (Tmem) differentiation and facilitated superior and long-lasting anti-tumor activity of chimeric antigen receptor (CAR) T cells, which suggests a potential target for enhancing anti-tumor immunity. The gene discussed is CD8A; the disease is neoplasm.